HomeHome SearchSearch MenuMenu Our productsOur products Ask an ExpertAsk an Expert

The newest injectable type 2 diabetes drug - what you need to know

by , 20 November 2017
The newest injectable type 2 diabetes drug - what you need to know
The US Food and Drug Administration (FDA) has approved a new injectable drug for adults with type 2 diabetes called Adlyxin (lixisenatide).

The once-daily injection is to be used in combination with a diabetic diet and regular exercise to keep patients' blood sugar levels steady.

Keep reading for more information that can help reduce the risk of type 2 diabetes-related complications such as blindness, heart disease and nerve and kidney damage...

The FDA reviewed the safety and effectiveness of Adlyxin – the newest injectable type 2 diabetes drug

The FDA reviewed 10 clinical trials to confirm the safety and effectiveness of Adlyxin. Overall, these studies included 5,400 people with type 2 diabetes. In addition, the FDA specifically tested for heart-related problems in 6,000 people at risk of heart disease.
 
The FDA concluded that Adlyxin helps regulate blood sugar level and that it doesn’t appear to increase the risk of heart disease and other heart problems.
 
So what exactly is Adlyxin?

***

Blood sugar worries? 
Get ready to sigh with sweet relief!
 
When this research first crossed my desk I couldn’t believe it!
 
The latest blood sugar science shows that your body’s own safety mechanism is why your current blood sugar solution may be selling you short.
 
In fact, this research confirms that targeting only your body’s natural insulin and your pancreas to conquer blood sugar is like trying to douse a forest fire with a glass of water.
 
But this research has also led to some really exciting news for you—a breakthrough in blood sugar science that no one saw coming.
 
Get ready to sigh with sweet relief!

***
 

Adlyxin is in a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists...

Adlyxin falls into the same class of drugs as liraglutide (Victoza), exenatide (Byetta, Bydureon) and dulaglutide (Trulicity), according to the American Diabetes Association.
 
While it treats type 2 diabetes, it shouldn’t be used to treat people with type 1 diabetes. It also shouldn’t be used by anyone with extremely elevated ketones (diabetic ketoacidosis) or even increased ketones (a sign that the body isn’t getting enough insulin) in their urine or blood, the FDA said.
 
The findings also showed that Adlyxin can present side effects such as such as headache, nausea, vomiting, dizziness and diarrhoea.
 
People who took both Adlyxin and other diabetes drugs such as long-acting (basal) insulin or sulfonylureas also had hypoglycaemia or low blood sugar. Furthermore, some people who took Adlyxin had hypersensitivity reactions including severe allergic reactions.
 
For more information on this new injectable type 2 diabetes drug, consult your doctor.

Vote article

The newest injectable type 2 diabetes drug - what you need to know
Rating:
Note: 5 of 1 vote

Related articles




Ask our Experts a Question

Linda Weech
Vanessa Jackson (BSc Anat&Phys, AEA, NLP)
Karin Iten, FSP Nutritionals, BA (Hons)
Nicqui Grant
Annabel Koffman

Related articles


Watch And Learn



Related Products

Resources